Myrexis Competitors

Acusphere (OTCMKTS:ACUS) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Acusphere and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Volatility and Risk

Acusphere has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Acusphere and Myrexis, as provided by MarketBeat.com.

Profitability

This table compares Acusphere and Myrexis' net margins, return on equity and return on assets.

Summary

Myrexis beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Affymax has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Valuation and Earnings

This table compares Affymax and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Affymax and Myrexis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Affymax and Myrexis, as provided by MarketBeat.com.

Summary

Affymax beats Myrexis on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

ARYx Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares ARYx Therapeutics and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ARYx Therapeutics and Myrexis' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for ARYx Therapeutics and Myrexis, as provided by MarketBeat.

Summary

Myrexis beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

AtheroNova has a beta of -8.71, suggesting that its stock price is 971% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares AtheroNova and Myrexis' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for AtheroNova and Myrexis, as provided by MarketBeat.

Summary

Myrexis beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

China Botanic Pharmaceutical has a beta of 17.09, suggesting that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares China Botanic Pharmaceutical and Myrexis' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for China Botanic Pharmaceutical and Myrexis, as provided by MarketBeat.

Summary

China Botanic Pharmaceutical beats Myrexis on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Myrexis (OTCMKTS:MYRX) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for China Dongsheng International and Myrexis, as provided by MarketBeat.

Volatility & Risk

China Dongsheng International has a beta of 13.38, suggesting that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares China Dongsheng International and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares China Dongsheng International and Myrexis' net margins, return on equity and return on assets.

Summary

China Dongsheng International beats Myrexis on 1 of the 1 factors compared between the two stocks.